69 items · search:archive
Daily average lexicon sentiment across 198 scored headlines over the last 8 days. For market-wide mood (VIX, breadth, regime), see Markets. For the learned model that predicts forward return from a headline, see Headline Forecast Model.
Crude prices retreated Wednesday and the pain landed squarely on exploration and production names, skipping refiners and midstream entirely. Here is why that mechanical link turned a commodity move into a sector-wide shakeout for some of the biggest names in the energy patch.
Bank stocks face inflation, rising rates, and debt-market uncertainty squeezing net interest marginsâclick to get insights on Fed policy and what to watch now.
Abbott Laboratories will pay $385 million to resolve claims tied to an investigation of contamination at a baby formula factory in Sturgis, Michigan, the largest in the country, which led to the supply shortages in 2022. Problems at the facility prompted a lawsuit by the Justice Department and recall of powdered infant formula at the facility. The recall covered several infant formula brands, including Similac, and squeezed inventory that had already been strained by supply chain disruptions and stockpiling during COVID-19 shutdowns.
Dollar Tree spent $8.5 billion to acquire Family Dollar — and then sold it off for $1 billion just a decade later. Fortune called it an "albatross." CNN called it "disastrous." But here's the twist: Dollar Tree's stock climbed 64% in 2025, with sales topping $19 billion.*Decode six of the boldest bets in business right now:* https://clickhubspot.com/8vxnThe two chains looked like natural partners — both dollar stores, both targeting budget shoppers. But underneath, they were built for completely different customers: Dollar Tree was a suburban treasure hunt for deals and novelty items; Family Dollar was an urban lifeline selling milk, eggs, and bread. Their warehouses were incompatible. Three years after the deal closed, they still had separate HQs, separate store operations teams, and separate tech systems.And yet somehow, the chaos of that failed merger is exactly what forced Dollar Tree to solve a problem that had been quietly threatening to kill it. This is the story of one of the strangest acquisitions in retail history — and what Dollar Tree quietly walked away with.0:00 Dollar-store turf war setup1:07 Meet the three “dollar” chains (who sells what, where)3:16 The 2015 bidding war: Why Dollar Tree beat Dollar General4:49 Incompatible supply chains and the rat-infested warehouse7:03 How debt, neglect, and understaffing broke Family Dollar stores8:40 The fatal flaw of the $1 promise: inflation and vendor squeeze9:23 Combo Stores: Using Family Dollar as Dollar Tree’s R&D lab10:24 The multi-price rollout and $1.25 era11:56 Private equity steps in: the leveraged buyout of Family Dollar13:31 Who pays the price: store closures, communities, and Dollar Tree’s takeawayGet the 5-minute newsletter keeping 2M+ innovators in the loop: https://thehustle.co/join-free-2
As continuous inflation squeezes household budgets, the discount retail sector should potentially benefit across the board, with middle- and lower-income consumers looking for value driving foot traffic into value chains. That’s roughly what happened in the second-quarter reports from Dollar General Corporation (NYSE:DG) and Dollar Tree, Inc. (NASDAQ:DLTR), both of which were released in late […]
Apple (AAPL) is selling iPhones and Macs faster than it can build them, but the number a holder should fear most is the gross margin underneath those sales. Leaving out tariff refunds, that margin fell in the June quarter and is guided lower again for the September quarter. Management puts both steps down to rising memory prices, while the stock's price-to-earnings multiple sits near the top of its 10-year range.
Brian Niccol, Starbucks CEO, joins 'Squawk Box' to discuss his first two years at the company and a new memo to employees on how the company has improved.
Oil hits $100 as the US-Iran war squeezes markets. Will AI growth prevent a recession, or is stagflation next? Read the IMF warning.
Fabio Osta, managing director and head of alternatives specialists team, EMEA wealth at BlackRock, told CNBC's "Squawk Box Europe" that markets are 'moving away' from the traditional 60/40 portfolio mix.
FMC Corporation is aggressively reducing debt and slashing costs at a potential ag industry cycle bottom. Click to read more on why FMC is rated Buy.
Bristol Myers Squibb reported positive Phase 2 results for its arlo-cel therapy, meeting key endpoints for multiple myeloma patients.
PRINCETON, N.J., September 08, 2026--Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial
Here are five key things investors need to know to start the trading day.
Trial met primary endpoint of overall response rate and key secondary endpoint of complete response rate in this heavily pretreated patient population who have been exposed to a prior BCMA-targeted therapyQUINTESSENTIAL
Goldman Sachs data suggests nearly half of all businesses could be running AI in daily operations within months, and the physical infrastructure scrambling to keep up has created a very specific set of winners. Five companies sit at the exact bottlenecks where that buildout cannot proceed without them.
The Future Fund's Gary Black warns Tesla may squander its autonomy and Cybercab lead by relying on technology alone.
BMY shows a strong breakout setup: 10/10 technical rating, 9/10 setup score. Rising moving averages and a buy stop at $68.10 make it one to watch.
Bristol Myers Squibb's aggressive M&A and in-house R&D efforts have driven the portfolio renewal cadence and ongoing valuation re-rating. Click for more on BMY.
A 1 million-square-foot data center is being built about 400 yards from a retired Phoenix homeowner’s paid-off house. He cannot prevent the development, so he is trying to decide whether to sell before it is completed or wait and risk...
In the most recent trading session, Bristol Myers Squibb (BMY) closed at $66.82, indicating a -1.87% shift from the previous trading day.
Eaton (ETN) is committing more than US$242 million to a new 1 million square foot facility in North Little Rock, Arkansas. The facility is intended to double Fibrebond’s U.S. capacity for customized electrical enclosures. For Eaton, the Arkansas expansion comes after a strong run in the share price, with a year to date share price return of 21.33%, even though the stock has pulled back with a 30 day share price decline of 10.71%. Recent news around increased Fibrebond capacity and upcoming...
Bristol Myers Squibb (BMY) has told regulators, researchers and patient groups in early June that it
Bristol Myers Squibb (BMY) stock: Strong Buy at 51% sector discount.
AI-driven memory cost surge is squeezing Nvidia, Broadcom, NetApp & Cisco margins. Click for this look at the sector and where it may be headed.
Bristol Myers Squibb's growth portfolio now drives nearly 60% of revenue, offsetting legacy drug declines and supporting total revenue growth. See why BMY stock is a Buy.
SoundHound AI could be a good candidate for a short squeeze.
Stock investing is all about balancing risk and reward, and nowhere is that more true than in short selling. Essentially, a short seller is betting that a stock will drop in price in the near-term; he sells ‘borrowed’ shares, hoping to close his position by buying them back, to return, at a lower price than he sold – and making a profit on the difference. The conventional wisdom on short selling is that it’s an indication of clear weakness in a stock. After all, large-scale short-selling is a li
Campbell’s reports weaker-than-expected quarterly earnings, while Tyson Foods lowers its revenue growth forecast citing volatile cattle prices and squeezed margins.
Despite Bristol-Myers Squibb's outperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.
Sam Altman just called out the AI compute buildout as heading toward unsustainable territory, and six publicly traded names are squarely in the crosshairs. Their disclosed contracts tell one story, but their debt loads and development pipelines tell another.
Reviewing prior stock picks is how investors turn experience into valuable feedback. A recommendation is only a thesis until the market tests it. Watch Doug discuss recent stock picks, provide input on the current market environment—and take your questions.
Bristol Myers Squibb (NYSE:BMY) has paused enrollment in its zola-cel cell therapy trials for autoimmune conditions following emerging safety concerns. The voluntary pause comes after inflammatory side effects were detected during ongoing safety surveillance in the program. The move raises fresh questions around the risk profile of cell-based therapies in autoimmune diseases, as well as the pace of Bristol Myers Squibb's clinical pipeline. For readers interested in more ideas in this corner...
Bristol-Myers Squibb (BMY) is back in focus after presenting long term Camzyos data from the EXPLORER-LTE cohort at the 2026 European Society of Cardiology Congress in Munich. Against this backdrop, Bristol-Myers Squibb’s share price has moved to US$66.92, with a 90 day share price return of 22.3% and a year to date share price return of 25.2%, while the 1 year total shareholder return of 47.9% points to stronger gains once dividends are included. Recent momentum has coincided with strong Q2...
Panmure Liberum has maintained its 'buy' rating on Oxford BioMedica PLC (LSE:OXB), the cell and gene therapy manufacturer, after its shares fell 15% following trial pauses by two of its customers. Novartis and Bristol Myers Squibb, both OXB customers, voluntarily paused enrolment in their...
The fintech loan facilitator’s second-quarter profit plunged as a funding squeeze in the wake of two major sector scandals forced it to scale back its business image credit: Bamboo Works Key
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how branded pharmaceuticals stocks fared in Q2, starting with Bristol-Myers Squibb (NYSE:BMY).
A global fuel squeeze is creating another refining windfall.
Victory Square Technologies Inc. ("Victory Square", "VST" or the "Company") (CSE: VST) (OTCQX: VSQTF) (FWB: 6F6), a venture builder focused on healthcare infrastructure, digital health, artificial intelligence and emerging technology platforms, today announced its financial results for the three and six months ended June 30, 2026, and provided an update on key portfolio developments.
GoPro stock is surging again Tuesday, marking gains of 140% from its 60 cent low last week.
The global non-melanoma skin cancer (NMSC) market is growing as basal cell carcinoma and squamous cell carcinoma rates rise due to UV exposure and aging populations. Advanced diagnostics, AI, targeted therapies, superficial radiation therapy and electronic brachytherapy are improving early detection and outcomes. North America leads the market, followed by Europe, while Asia-Pacific is expanding rapidly. Key players include Amgen, Regeneron, Almirall and Boehringer Ingelheim. FDA-approved Libtay
On August 28, Affirm Holdings (NASDAQ:AFRM) gave investors two very different signals in the same breath. The buy now, pay later company posted a fiscal fourth quarter that blew past Wall Street’s numbers, yet CEO Max Levchin used the moment to flag something less comfortable: gas prices are squeezing the very shoppers driving that growth. […]
ALB and SQM are ramping capacity and expanding output as EV and storage demand accelerates.
Sociedad QuÃmica y Minera de Chile is rated a Hold, with a $106 YE27 price target, reflecting flat long-term net income. Read more on SQM stock here.
Qfin Holdings faces rising risk metrics, a contracting loan environment, and a one-off RMB 500mn tax hit. Read more on QFIN stock here.
Most of that gap looks like a squeeze unwinding, but the shocks this stock has traded through show a name that falls much harder than the market.
Lithium stocks split: profitable producers like SQM, Albemarle rebound, while pre-revenue battery tech names lag. Market rewards profits, not promises.
Citrini Research predicts a Treasury twist in the market, with banks replacing the Fed as buyers of government debt, leading to a potential short squeeze on 30-year bonds.
OMAHA, Neb. & ATLANTA, August 26, 2026--Union Pacific and Norfolk Southern demonstrated today that opponents’ prima facie challenges should be squarely rejected. In their response filing, the railroads emphasized that their application, which includes extensive evidence and represents months of work, easily satisfies the Surface Transportation Board’s (STB) threshold requirements. It gives the STB everything it needs to begin its full review and provides overwhelming confirmation that the propos
The facilities will add more than 500,000 square feet of air cargo space as India looks to more than double its national handling capacity by 2030.
For long-suffering owners of Boston Scientific, here’s how to get paid a meaningful cash income now, yours to keep no matter what, in exchange for capping your gains at a higher price.
Ondas, SoundHound AI and CleanSpark are in the top ten most-heavily shorted stocks in the market right now.
Qfin Holdings Inc (QFIN) reports a challenging quarter with significant revenue decline, but strengthens provisions and advances tech solutions growth amid industry-wide liquidity squeeze.
Moderna stock surged following positive cancer-vaccine data, burning short sellers and spilling over into the semi sector.
Palantir squeezes short sellers in a market rally, with $12 billion in short interest and $5 billion in losses.
Pershing Square's Q2 2026 13F portfolio surged to $19.47B, expanding from 10 to 14 positions. Check out the portfolio here.
Pershing Square took multiple new positions in the second quarter. A look at the portfolio changes and top holdings.
Pershing Square reports H1 2026 performance results and long-term EPS growth estimates for its portfolio. Read the full analysis for more details.
Hertz was one of the worst-performing stocks in Pershing Square’s investment portfolio this year through August 11, subtracting 1.1% from gross performance, the firm said.
Pershing Square Capital Management exited its position in Hertz after the company announced an equity offering in June, the hedge fund says.
Hertz Global Holdings Inc. shares tumbled as Pershing Square Inc.’s chief investment officer said the asset management firm has sold its stake in the car-rental company.
DuPont (NYSE: DD) today announced that its Direct Lithium Extraction (DLE) team has been named a "Sustainability Squad" in the Business Intelligence Group's 2026 Sustainability Awards. The DuPont DLE team was recognized for its work over the past year helping develop, validate, and commercialize direct lithium extraction technologies that support effective and efficient lithium recovery and support scalable lithium production amid accelerating global demand.
Hertz Global Holdings Inc. (NASDAQ: HTZ) stock fell after Bill Ackman's Pershing Square exited its position, interrupting a retail rally driven by Q2 earnings and high short interest.
Dover stock has delivered a strong 54.9% return over the last three years, while the latest Discounted Cash Flow (DCF) intrinsic value estimate points to the shares trading below that model's fair value, even though market multiples suggest pricing is roughly in line with peers. That mixed message puts the focus squarely on whether the current US$208.07 share price already reflects the key drivers of future cash flows. The 54.9% gain over three years highlights that Dover has already...
Live entertainment leader Madison Square Garden Entertainment blows past earnings estimates as revenue growth sharply accelerates.
Lithium & battery stocks split: profitable GM, SQM, Albemarle lead rebound; unprofitable Enovix, QuantumScape lag. Focus on earnings.
Hertz shares are trading marginally lower on Wednesday as the stock digests the recent retail-driven squeeze narrative and heavy short-interest chatter.
Niu Technologies stock plunged after swinging to a Q2 loss and gross margin contraction, despite a 14.7% rise in revenue.
Peabody, Mass. (01960) joins the Hottest ZIPs for the third time since previously ranked No. 5 in 2018 and No.3 in 2021. For the fourth consecutive year, the Northeast and Midwest swept the rankings, with this year's list underscoring a clear shift in what today's buyers are willing to pay for: more square footage and established character, even if it means a longer commute or a smaller discount versus the surrounding metro.
Hertz stock is soaring on huge trading volumes since it reported strong earnings on Thursday. More than 28% of the public float faces a short interest.